Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors

Various staging systems have been proposed for disseminated germ cell neoplasms. The Indiana University staging system was based on clinical and radiographic findings only, whereas the newly created International Germ Cell Cancer Collaborative Group (IGCCCG) staging system also utilized serum markers as a prognostic factor. This study updated the intergroup trial that compared the standard therapy of bleomycin, etoposide, and cisplatin (BEP) with etoposide, ifosfamide, and cisplatin (VIP) in advanced germ cell tumors and reanalyzed the results using the IGCCCG staging system.

[1]  L. Einhorn.  Treatment of testicular cancer: a new and improved model. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Catalano,et al.  Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[4]  L. Einhorn,et al.  Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. , 1993, Journal of the National Cancer Institute.

[5]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Sylvester,et al.  High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[8]  P. Albers,et al.  Late relapse of testicular cancer , 2004, World Journal of Urology.

[9]  G. Brodeur,et al.  Down's syndrome and leukemia: epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. , 1987, Cancer genetics and cytogenetics.

[10]  A. Horwich,et al.  The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Einhorn,et al.  Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  L. Einhorn,et al.  The role of maintenance therapy in disseminated testicular cancer. , 1981, The New England journal of medicine.

[13]  R. Sylvester,et al.  Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study. , 1987, Cancer research.

[14]  L. Einhorn,et al.  Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Horsman,et al.  Therapy-related acute myelogenous leukemia associated with 11q23 chromosomal abnormalities and topoisomerase II inhibitors: report of four additional cases and brief commentary. , 1993, Leukemia & lymphoma.

[16]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[17]  N. Heerema,et al.  Hematologic neoplasia associated with primary mediastinal germ-cell tumors. , 1990, The New England journal of medicine.

[18]  C. Théodore,et al.  Prognostic factors in advanced nonseminomatous testicular cancer a multivariate logistic regression analysis , 1988, Cancer.

[19]  L. Einhorn,et al.  Prognostic factors for favorable outcome in disseminated germ cell tumors. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  N. Geller,et al.  Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. , 1983, Cancer research.

[21]  C. Meisner,et al.  Identification of prognostic subgroups among patients with metastatic 'IGCCCG poor-prognosis' germ-cell cancer: an explorative analysis using cart modeling. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.